Concomitant administration of the ?-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide

Kleist, Peter; Ehrlich, A.; Suzuki, Yoshiharu; Timmer, Wolfgang; N, Wetzelsberger; Lücker, Peter Wolfgang; Fuder, H.

doi:10.1007/s002280050354

Cited by 16 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Moreover, the pharmacokinetics of Glibenclamide was also not affected by the concurrent use of Voglibose the other α-glucosidase inhibitor. 25…”

Section: Sulfonylureasmentioning

confidence: 99%

Pharmacologically relevant drug interactions of α glucosidase inhibitors

Maideen¹

2019

JDMDC

View full text Add to dashboard Cite

The α-glucosidase inhibitors are antidiabetic agents suppressing the postprandial hyperglycemia and they include Acarbose, Miglitol and Voglibose. These drugs could be used alone or as add-on therapy to treat patients with type 2 diabetes taking other antidiabetic drugs. The gastrointestinal motility is increased by the administration of Acarbose, which may lead to decreased absorption of Digoxin and Metronidazole. The glucose lowering effects of antidiabetic drugs such as Metformin, Glibenclamide, Rosiglitazone, Vildagliptin and Dapagliflozin might be enhanced by the coadministration of α-glucosidase inhibitors, though there were reports of little or no alterations in the pharmacokinetics properties of them.

show abstract

“…24 Moreover, the pharmacokinetics of Glibenclamide was also not affected by the concurrent use of Voglibose the other α-glucosidase inhibitor. 25…”

Section: Sulfonylureasmentioning

confidence: 99%

Pharmacologically relevant drug interactions of α glucosidase inhibitors

Maideen¹

2019

JDMDC

View full text Add to dashboard Cite

show abstract

“…We observed two reasons for the absence of validation data in the articles: the study was performed before the guidelines had been published [53][54][55][56][57][58][59][60][61][62][63][64][65][66]; and the study focus was on method development and validation was not addressed [67][68][69][70][71][72]. Other reasons for excluding articles were: non-simultaneous method [74][75][76][77], inappropriate sample preparation [78,79], literature review [80], animal plasma sample [81], language in non-Roman characters [82][83][84], validation of only one analyte [85,86], and pharmacokinetic studies (PK) that used a previously developed and validated method [87][88][89][90][91][92][93][94][95][96][97].…”

Section: Systematic Literature Searchmentioning

confidence: 99%

A systematic and critical review on bioanalytical method validation using the example of simultaneous quantitation of antidiabetic agents in blood

Fachi

Leonart

Cerqueira

et al. 2017

Journal of Chromatography B

View full text Add to dashboard Cite

A systematic and critical review was conducted on bioanalytical methods validated to quantify combinations of antidiabetic agents in human blood. The aim of this article was to verify how the validation process of bioanalytical methods is performed and the quality of the published records. The validation assays were evaluated according to international guidelines. The main problems in the validation process are pointed out and discussed to help researchers to choose methods that are truly reliable and can be successfully applied for their intended use. The combination of oral antidiabetic agents was chosen as these are some of the most studied drugs and several methods are present in the literature. Moreover, this article may be applied to the validation process of all bioanalytical.

show abstract

“…The carbasugar AO-128 (Voglibose) is also an -glucosidase inhibitor and has been shown to exert anti-obesity activity Carbohydrate-based therapeutics in addition to its anti-diabetic action. Voglibose is well tolerated and may be used in combination with other drugs such as glibenclamide (Kleist et al 1997). Miglitol is an oral -glucosidase inhibitor and is used in the treatment of non-insulin-dependent diabetes mellitus.…”

Section: Inhibition Of Enzymes That Synthesize Disease-associated Carmentioning

confidence: 99%

Carbohydrate-based therapeutics

Osborn

Evans

Gemmell

et al. 2004

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

In recent years there has been a resurgence of interest in the biological roles of carbohydrates and as a result it is now known that carbohydrates are involved in a vast array of disease processes. This review summarises progress in the development of carbohydrate-based therapeutics that involve: inhibition of carbohydrate-lectin interactions; immunisation, using monoclonal antibodies for carbohydrate antigens; inhibition of enzymes that synthesise disease-associated carbohydrates; replacement of carbohydrate-processing enzymes; targeting of drugs to specific disease cells via carbohydrate-lectin interactions; carbohydrate based anti-thrombotic agents.

show abstract

Concomitant administration of the ?-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide

Abstract: Voglibose did not interact with glibenclamide on a pharmacokinetic level. Concomitant treatment was well tolerated and has been proven to be safe for further clinical use.

Cited by 16 publications

References 6 publications

Pharmacologically relevant drug interactions of α glucosidase inhibitors

Pharmacologically relevant drug interactions of α glucosidase inhibitors

A systematic and critical review on bioanalytical method validation using the example of simultaneous quantitation of antidiabetic agents in blood

Carbohydrate-based therapeutics

Contact Info

Product

Resources

About